NCT04429087 - A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

September 1, 2026

Study Completion Date

February 15, 2027

Conditions

Patients With Small Cell Lung Carcinoma and Other Neoplasms

Interventions

DRUG

BI 764532 - parenteral 1

DRUG

BI 764532 - parenteral 2

Trial Locations (12)

15232

COMPLETED

University of Pittsburgh Medical Center, Pittsburgh

21201

RECRUITING

University of Maryland School of Medicine, Baltimore

30322

RECRUITING

Winship Cancer Institute, Atlanta

31008

RECRUITING

Clínica Universidad de Navarra, Pamplona

46010

RECRUITING

Hospital Clínico de Valencia, Valencia

50937

RECRUITING

Universitätsklinikum Köln (AöR), Cologne

63108

RECRUITING

Washington University School of Medicine, St Louis

97078

RECRUITING

Universitätsklinikum Würzburg AÖR, Würzburg

01307

RECRUITING

Technische Universität Dresden, Dresden

277-8577

RECRUITING

National Cancer Center Hospital East, Chiba, Kashiwa

08003

RECRUITING

Hospital del Mar, Barcelona

08035

RECRUITING

Hospital Universitari Vall D Hebron, Barcelona